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The importance of Medicaid as a source of funding for HIV/AIDS treatment of low-income persons will grow substantially after full implementation of the Affordable Care Act, which eliminates the additional disability requirement for Medicaid eligibility in states accepting the Medicaid expansion, thereby extending coverage to nondisabled, low-income PLWHA in those states.
Because of its prominent role in insuring low-income PLWHA, Medicaid can provide a rich source of data on the types and costs of treatments delivered to some of the most vulnerable individuals with HIV/AIDS.
Insurance claims data can potentially allow us to monitor HIV/AIDS treatment without substantial new investments because most claims data are stored as computerized records. Claims data provide a comprehensive picture of medical care received from a variety of providers in multiple settings (outpatient, inpatient, laboratory, pharmacy), contain procedure codes that detail the services provided, and include cost of the treatment. In contrast, medical records tend to have smaller scope, in terms of both numbers of patients and services covered. Furthermore, medical records most often lack payment information.
Insurance claims data can provide information on a large number of individuals, even among those with relatively low-prevalence conditions, which is valuable in reducing the variability of estimates of per capita expenditures. However, the greater precision afforded by large administrative data sets is of little value if estimates are based on an inappropriate sample. Claims data are primarily designed for billing purposes; thus, they generally lack clinical detail important for selecting cases with a particular disease. 5, 6 For example, claims , , data will document whether a laboratory test was performed, but not the test result. Therefore, analysts must rely on the diagnosis information on insurance claims. 7 Professional medical records specialists code diagnoses on inpatient claims, leading to greater accuracy and reliability of diagnosis information coming from inpatient stays. However, diagnosis coding is more error-prone in the outpatient sector, which has accounted for an increasing percentage of HIV/AIDS care since 1996 when antiretroviral medication (ARV) began to dramatically reduce hospitalization for HIV/AIDS. 8 This has increased the challenges of identifying PLWHA from insurance claims data.
We applied a practical algorithm for identifying PLWHA in insurance claims data to estimate Medicaid costs for treating HIV/AIDS in California. We also examined how alternate methods of identifying the relevant sample affect estimates of per capita costs. We also dropped individuals enrolled in managed care. Nearly half (46%) of the full-benefit Medi-Cal enrollees were dually enrolled in both Medicare and Medi-Cal. For these individuals, Medicare is the primary payer, and the bulk of their care would be expected in the Medicare claims data. However, there are no claims or encounter data available for care received under Medicare managed care, and thus no opportunity to identify HIV-positive persons through diagnosis codes recorded in Medicare claims. Therefore we limited our analysis to these enrolled in fee-for-service (FFS) care only.
METHODS

Development of Classifications for Confirmed Diagnoses
We refer to the resulting file as the "Any DX/ARV" file, as FFS enrollees are included if they had at least 1 HIV/AIDS diagnosis code included anywhere in the claims data or, and/or any drug claims for ARV medications. Diagnosis coding is notably subject to error-both random error and miscoding of "rule-out diagnoses." Peabody et al. found that only 57% of administrative records had the correct primary diagnosis coded. 5 To address the errors typically found in diagnosis coding, [5] [6] [7] [8] [10] [11] [12] [13] we developed 2 criteria for adding a record to a confirmed HIV/AIDS file.
The inpatient-2 visit criterion required an HIV diagnosis code coded in an inpatient claim, or in at least 2 outpatient claims, spaced at least 1 month apart. The strategy of requiring that a diagnosis appear twice in the claims has been endorsed by many analysts. Rector et al. 16 also proposed an algorithm based on HIV-specific diagnosis codes, procedure codes, and ARV use.
The nonscreening criterion required a diagnosis coded in an outpatient setting on a day when HIV screening tests were not performed. There is evidence that rule-out diagnoses sometimes remain in the claims even after the condition has been ruled out, 17 so we did not consider a sole diagnosis occurring on the same day as an HIV screening examination, on its own, sufficient evidence of HIV infection. Therefore, the nonscreening criterion required an HIV diagnosis recorded in an outpatient claim on at least 1 day when there was not also an HIV antibody screening test.
Although the initial file requested from CMS included individuals on the basis of ARV use, we did not continue to use that as an inclusion criterion. Some ARV regimens can also be used in the treatment of hepatitis We present frequencies of treatment of each classification group by program enrollment (Medi-Cal-only enrollees, dual Medicare-Medi-Cal enrollees, and total). We performed χ 2 tests to determine whether the rates of treatment differ significantly between the confirmed and excluded cases.
For each group, we also calculated annual per capita expenditures by summing all paid medical and pharmaceutical claims for each individual. We annualized expenditures of part-year enrollees who did not die during the year. We did not change expenditures of those who died during the year. We performed t tests to determine whether mean spending differed significantly between the confirmed and excluded cases. Table   1 ). Fifty-two percent (10|941) were enrolled in Medi-Cal only and 48% (10|059) were covered by both the Medi-Cal and Medicare programs, the "dual eligibles" (Table 1 Table 2 ).
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Eighty percent of individuals in the confirmed file filled prescriptions for ARV drugs, compared with 59% of the excluded cases. This 59% includes those who had an ARV claim but no HIV/AIDS diagnosis code. There was less-frequent ARV use among those included by the expanded definition (39% using ARVs vs 85% among those meeting both inclusion criteria).
Evidence of HBV infection, through diagnosis or HBV-consistent use of ARVs, was greatest among the excluded group (37% vs 7% in the confirmed file; Table 2 ).
All differences in treatment were statistically significant, with χ 2 P values less than .001.
Expenditures
Annual expenditures were greatest within the Medi-Cal-only group among persons meeting the strict definition for inclusion ($36|469; Table 2 ). The PLWHA added via the expanded definition had lower average costs ($19|184). Expenditures averaged $33|720 for the confirmed HIV/AIDS file without dual coverage.
Spending for the excluded cases was 27% lower ($24|514 per year).
Persons in the confirmed HIV/AIDS file with dual coverage had annual Medi-Cal expenditures of $7003
and Medicare expenditures of $39|046. Thus, although dual enrollees had greater total medical expenditures ($46|050) than persons with only Medi-Cal, Medi-Cal costs were much lower for duals because Medicare paid for the largest share of the duals' medical spending. Part-year enrollment is more common among Medi-Calonly beneficiaries, who averaged nearly a month less coverage during the year than enrollees with dual coverage. Without annualizing, the spending estimates for Medi-Cal-only beneficiaries would appear 11% lower. 
DISCUSSION
Insurance claims data have many advantages for examining the quality and cost of medical treatment of relatively low-prevalence diseases such as HIV. Claims data include the full range of treatment servicesoutpatient and inpatient care as well as long-term care, medication, laboratory, and support services. The validity of the claims data are high as they report what was actually paid by the insurer and are not subject to erroneous recall of either use or diagnosis by patients, as survey data might be. It would also be prohibitively expensive to gather information on such a large number of patients with a relatively low-prevalence disease such as HIV/AIDS by using population-based surveys 7 or by combining data from electronic medical records across providers, each with only a small number of relevant patients. Furthermore, clinical electronic medical records most often lack billing and reimbursement data, so analysts must estimate costs by applying price schedules to utilization data. 19 Despite these advantages, identifying the relevant population from claims can be challenging. Reports from early in the HIV epidemic also noted the promise of studying HIV by using Medicaid claims data, and noted the difficulties in using a diagnosis-based algorithm for identifying cases. In 1991, Keyes et al. identified the problem as undercounting of HIV cases because of changing definitions and nonreporting of diagnoses resulting from attempts to protect patients from stigma. 13 Our analysis indicates that currently the problem is more likely to be overcounting: a substantial proportion of the initial CMS sample had received HIV screening, but did not have other indications of HIV disease. Including these "HIV screeners" in the population used to assess quality of care, disparities, or costs of HIV care could lead to misleading results. 11 In an illustration of the importance of properly identifying PLWHA, a recent publication reported that only 21% of a large sample of Medicaid recipients newly diagnosed with HIV followed up with HIV treatment 20 However, the analysis sample appeared to include people with a single HIV diagnosis that could have been reported in conjunction with their HIV screening tests. As argued previously, this strategy can include many individuals without HIV disease, who did not seek (and did not need) HIV treatment. 12 Similarly, Zhang and coauthors 21 reported that 37.3% of HIV-positive Medicaid-enrolled pregnant women received no ARV treatment in pregnancy. As screening pregnant women for HIV is the standard of care, 22 this method may include many who were only screened for HIV, but did not have HIV disease. The algorithm we propose addresses the HIV-specific challenges in identifying PLWHA from claims data files, including coding errors such as miscoding of rule-out diagnoses.
Using Claims Data to Estimate HIV Treatment Costs
Accurately identifying actual HIV cases in the claims data has potentially large policy implications because managed care capitation rates are frequently based on calculated levels of FFS spending 23 and the true costs of treating HIV will be underestimated if the estimation sample includes individuals without HIV disease, especially if HIV screening is more likely to be performed among younger and healthier groups.
[ID]FIG2[/ID] Figure 2 , which relates to Medi-Cal spending for both Medi-Cal and dual beneficiaries, illustrates that each of the adjustments that we have made (limiting the sample to those with full Medi-Cal benefits, removing managed care enrollees, including only confirmed cases, and annualizing expenditures of part-year enrollees) increases the estimate of per capita Medi-Cal spending on HIV. Further, per capita spending levels are significantly higher in each group for persons with Medi-Cal only, because the vast majority of the treatment costs for those dually eligible for Medicaid and Medicare are borne by Medicare, as shown in Figure   2 . Thus, although duals had significantly higher total treatment costs than Medi-Cal-only beneficiaries, the costs paid by Medi-Cal were lower. 
Limitations
Our analysis is subject to some limitations. Although the algorithm we propose deletes from the confirmed HIV sample persons most likely to have been assigned an HIV diagnosis code erroneously, it is possible that some of the individuals with only a rule-out diagnosis or other data errors may remain in the sample. However, available evidence strongly supports the distinctions between the HIV sample included under the strict definition (80% of whom had evidence of viral load or CD4 testing) and the excluded group (in which only 3% had viral load or CD4 testing). The high prevalence of HBV diagnoses or HBV-consistent use of ARVs among the excluded group (37% vs 7% in the confirmed file; Table 2) confirms that this exclusion was likely effective.
In addition to this strict definition group with the strongest evidence of HIV infections, there is a group of people that did not have diagnoses recorded on multiple visits, but did receive an HIV diagnosis on a nonscreening day. One third of people in this group received viral load or CD4 tests, and 39% had claims for ARVs. The cases added under the expanded definition, especially among dual enrollees, included a larger proportion of females, suggesting that we may have added some cases in which a rule-out diagnosis was recorded in conjunction with a screening test, but did not appear in the claims on the same day.
Although we are less confident that everyone in this latter group is actually HIV-positive, there is enough evidence of some infection that it is difficult to ignore them. Using criteria for inclusion that are too strict will 
Conclusions
As outpatient care for PLWHA continues to increase and HIV screening tests become a routine part of medical care, as recommended by the Centers for Disease Control and Prevention, 28 it becomes increasingly important to be able to identify PLWHA in health insurance claims data to assess the cost and quality of HIV care rendered by different providers. This is particularly true for public insurance programs. Medicare and Medicaid account for more than three quarters of domestic federal spending on HIV/AIDS treatment 29 and in California these 2 programs covered almost half of PLWHA in 2007. 30 As publicly funded insurance, these programs are of particular importance to policymakers as they seek to monitor the cost and quality of treatments received by publicly insured PLWHA and to set managed care 
